Virtus Investment Advisers, Inc. Biotechnology

Virtus Investment Advisers, Inc.

$286 Million
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
CRVS Corvus Pharmaceuticals, Inc.	$209M	$88,000 0.03% of portfolio	22,177	Q2 2025 Added 9.17%
REPL Replimune Group, Inc.	$259M	$88,000 0.03% of portfolio	9,513	Q2 2025 Reduced 29.19%
PCVX Vaxcyte, Inc.	$1.78B	$88,000 0.03% of portfolio	2,729	Q2 2025 Added 45.78%
VKTX Viking Therapeutics, Inc.	$3.06B	$87,000 0.03% of portfolio	3,290	Q2 2025 Reduced 4.08%
TYRA Tyra Biosciences, Inc.	$445M	$87,000 0.03% of portfolio	9,103	Q2 2025 Reduced 15.85%
BLTE Belite Bio, Inc	$1.83B	$87,000 0.03% of portfolio	1,513	Q2 2025 Reduced 41.56%
GLUE Monte Rosa Therapeutics, Inc.	$208M	$86,000 0.03% of portfolio	19,112	Q2 2025 Reduced 9.31%
KYMR Kymera Therapeutics, Inc.	$2.18B	$86,000 0.03% of portfolio	1,988	Q2 2025 Reduced 48.91%
WVE Wave Life Sciences Ltd.	$734M	$84,000 0.03% of portfolio	13,060	Q2 2025 Added 10.21%
JANX Janux Therapeutics, Inc.	$1.01B	$84,000 0.03% of portfolio	3,679	Q2 2025 Added 37.89%
CRNX Crinetics Pharmaceuticals, Inc.	$1.53B	$84,000 0.03% of portfolio	2,923	Q2 2025 Reduced 1.02%
RVMD Revolution Medicines, Inc.	$3.09B	$84,000 0.03% of portfolio	2,287	Q2 2025 Reduced 37.38%
ANNX Annexon, Inc.	$116M	$83,000 0.03% of portfolio	34,698	Q2 2025 Reduced 4.67%
VRDN Viridian Therapeutics, Inc.\De	$717M	$83,000 0.03% of portfolio	6,001	Q2 2025 Reduced 34.26%
RNA Avidity Biosciences, Inc.	$2.41B	$83,000 0.03% of portfolio	2,926	Q2 2025 Reduced 39.79%
SNDX Syndax Pharmaceuticals Inc	$734M	$82,000 0.03% of portfolio	8,813	Q2 2025 Reduced 27.71%
IMTX Immatics N.V.	$489M	$82,000 0.03% of portfolio	15,315	Q2 2025 Reduced 30.87%
KALV Kal Vista Pharmaceuticals, Inc.	$301M	$81,000 0.03% of portfolio	7,184	Q2 2025 New
QURE Uni Qure N.V.	$668M	$81,000 0.03% of portfolio	5,881	Q2 2025 Reduced 46.08%
LQDA Liquidia Corp	$1.55B	$81,000 0.03% of portfolio	6,507	Q2 2025 Reduced 56.36%
TSHA Taysha Gene Therapies, Inc.	$141M	$81,000 0.03% of portfolio	35,484	Q2 2025 Reduced 51.36%
RCUS Arcus Biosciences, Inc.	$698M	$81,000 0.03% of portfolio	10,057	Q2 2025 Added 5.07%
KURA Kura Oncology, Inc.	$415M	$81,000 0.03% of portfolio	14,119	Q2 2025 Reduced 16.66%
ABUS Arbutus Biopharma Corp	$510M	$81,000 0.03% of portfolio	26,266	Q2 2025 Reduced 43.04%
TRDA Entrada Therapeutics, Inc.	$162M	$80,000 0.03% of portfolio	11,979	Q2 2025 Added 32.15%
CGEM Cullinan Oncology, Inc.	$332M	$79,000 0.03% of portfolio	10,506	Q2 2025 Reduced 21.92%
EWTX Edgewise Therapeutics, Inc.	$846M	$79,000 0.03% of portfolio	6,098	Q2 2025 Added 4.61%
XNCR Xencor Inc	$463M	$78,000 0.03% of portfolio	9,972	Q2 2025 Added 50.32%
ERAS Erasca, Inc.	$191M	$78,000 0.03% of portfolio	61,459	Q2 2025 Reduced 1.54%
ALLO Allogene Therapeutics, Inc.	$148M	$75,000 0.03% of portfolio	67,166	Q2 2025 Reduced 17.35%
RGNX Regenxbio Inc.	$350M	$75,000 0.03% of portfolio	9,219	Q2 2025 Reduced 51.04%
RCKT Rocket Pharmaceuticals, Inc.	$220M	$75,000 0.03% of portfolio	30,630	Q2 2025 Added 134.57%
BCYC Bicycle Therapeutics PLC	$214M	$75,000 0.03% of portfolio	10,821	Q2 2025 Added 32.58%
CAPR Capricor Therapeutics, Inc.	$196M	$66,000 0.02% of portfolio	6,746	Q2 2025 Reduced 41.07%
DYN Dyne Therapeutics, Inc.	$602M	$61,000 0.02% of portfolio	6,503	Q2 2025 Added 1.4%
ALT Altimmune, Inc.	$177M	$50,000 0.02% of portfolio	13,151	Q2 2025 Reduced 31.2%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.